What is Globus Medical's operating income?

Globus Medical's total operating income in 2025 was $479.82 million, based on the following breakdown: Total Gross Profit: $1.98 billion Total Operating Expenses: $1.50 billion

Globus Medical (GMED) Financials

$78.36 -1.64 (-2.05%)

Closing price 03:59 PM Eastern

Extended Trading

$79.37 +1.01 (+1.29%)

As of 07:40 PM Eastern

Compare

Annual Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	113	104	107	156	155	102	149	190	123	103	538
Consolidated Net Income / (Loss)	113	104	107	156	155	102	149	190	123	103	538
Net Income / (Loss) Continuing Operations	113	104	107	156	155	102	149	190	123	103	538
Total Pre-Tax Income	173	157	170	189	190	126	180	243	165	121	605
Total Operating Income	172	154	162	169	172	111	172	228	133	166	480
Total Gross Profit	412	429	486	554	605	572	719	759	1,020	1,484	1,981
Total Revenue	545	564	636	713	785	789	958	1,023	1,568	2,519	2,939
Operating Revenue	545	564	636	713	785	789	958	1,023	1,568	2,519	2,939
Total Cost of Revenue	132	135	150	159	180	217	239	264	548	1,035	958
Operating Cost of Revenue	132	135	150	159	180	217	239	264	548	1,035	958
Total Operating Expenses	240	275	324	384	433	460	547	531	887	1,318	1,501
Selling, General & Admin Expense	210	222	268	312	355	355	408	432	644	981	1,178
Research & Development Expense	36	45	44	55	60	85	97	73	124	164	147
Amortization Expense	1.56	3.48	7.91	9.59	14	17	19	18	51	119	118
Restructuring Charge	3.35	1.83	1.61	1.68	2.58	4.03	17	5.96	68	53	57
Total Other Income / (Expense), net	1.17	3.14	8.09	19	18	14	8.45	15	32	-45	125
Interest & Investment Income	-	-	-	-	-	-	-	-	20	-4.19	7.14
Other Income / (Expense), net	-0.14	0.08	1.48	6.00	0.55	0.51	-0.84	0.84	12	-41	118
Income Tax Expense	60	53	63	32	35	24	31	53	43	18	67
Basic Earnings per Share	$1.19	$1.09	$1.12	$1.60	$1.57	$1.04	$1.48	$1.89	$1.09	$0.76	$3.98
Weighted Average Basic Shares Outstanding	95.05M	95.65M	96.24M	97.88M	99.15M	98.58M	100.73M	100.47M	113.09M	135.73M	135.22M
Diluted Earnings per Share	$1.17	$1.08	$1.10	$1.54	$1.52	$1.01	$1.44	$1.85	$1.07	$0.75	$3.92
Weighted Average Diluted Shares Outstanding	96.07M	96.43M	97.89M	101.32M	102.00M	100.97M	103.62M	102.64M	114.63M	137.86M	137.06M
Weighted Average Basic & Diluted Shares Outstanding	94.80M	95.70M	95.80M	97.80M	99.84M	99.80M	101.56M	100.30M	135.37M	137.54M	135.25M

This table shows Globus Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	1.00	15	-7.12	32	52	27	75	203	119	141	124
Consolidated Net Income / (Loss)	1.00	15	-7.12	32	52	27	75	203	119	141	124
Net Income / (Loss) Continuing Operations	1.00	15	-7.12	32	52	27	75	203	119	141	124
Total Pre-Tax Income	2.54	25	-8.56	48	57	25	104	188	144	169	157
Total Operating Income	0.40	10	8.00	50	48	60	97	76	137	169	150
Total Gross Profit	248	351	365	370	355	394	403	497	517	565	526
Total Revenue	384	617	607	630	626	657	598	745	769	826	760
Operating Revenue	384	617	607	630	626	657	598	745	769	826	760
Total Cost of Revenue	135	265	241	260	271	263	195	249	253	261	234
Operating Cost of Revenue	135	265	241	260	271	263	195	249	253	261	234
Total Operating Expenses	248	341	357	320	307	334	306	420	379	396	375
Selling, General & Admin Expense	156	245	249	239	240	253	243	304	314	318	298
Research & Development Expense	29	52	57	38	35	33	33	40	38	36	37
Amortization Expense	14	28	30	30	30	30	29	30	30	29	30
Restructuring Charge	46	16	22	13	1.57	17	1.06	47	-2.36	12	12
Total Other Income / (Expense), net	2.13	15	-17	-2.04	8.93	-36	6.66	112	6.63	-0.11	6.69
Interest & Investment Income	-	-	-	-	-	-	1.68	-	-	-	5.43
Other Income / (Expense), net	-5.79	17	-15	0.29	9.71	-36	4.98	111	5.18	-3.42	1.25
Income Tax Expense	1.54	9.96	-1.44	16	5.20	-1.84	28	-15	25	29	33
Basic Earnings per Share	$0.01	$0.02	($0.05)	$0.23	$0.38	$0.20	$0.55	$1.50	$0.88	$1.05	$0.92
Weighted Average Basic Shares Outstanding	113.54M	113.09M	135.36M	135.20M	135.62M	135.73M	136.76M	135.21M	134.50M	135.22M	135.36M
Diluted Earnings per Share	$0.01	$0.01	($0.05)	$0.23	$0.38	$0.19	$0.54	$1.49	$0.88	$1.01	$0.90
Weighted Average Diluted Shares Outstanding	115.25M	114.63M	135.36M	136.98M	138.06M	137.86M	139.77M	136.50M	135.39M	137.06M	138.19M
Weighted Average Basic & Diluted Shares Outstanding	137.79M	135.37M	135.06M	135.41M	136.17M	137.54M	135.38M	135.06M	133.84M	135.25M	135.74M

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-25	-16	51	21	56	44	-46	-43	315	317	-281
Net Cash From Operating Activities	124	148	159	182	172	199	276	178	243	521	753
Net Cash From Continuing Operating Activities	124	148	159	182	172	199	276	178	243	521	753
Net Income / (Loss) Continuing Operations	113	104	107	156	155	102	149	190	123	103	538
Consolidated Net Income / (Loss)	113	104	107	156	155	102	149	190	123	103	538
Depreciation Expense	24	39	42	42	53	63	70	68	146	253	277
Amortization Expense	3.35	4.07	2.67	1.68	-1.09	0.59	2.78	5.39	80	242	26
Non-Cash Adjustments To Reconcile Net Income	9.87	24	28	30	32	72	72	37	52	119	-53
Changes in Operating Assets and Liabilities, net	-26	-23	-21	-48	-67	-39	-18	-122	-157	-197	-35
Net Cash From Investing Activities	-153	-163	-111	-193	-140	-117	-376	-110	303	-176	-355
Net Cash From Continuing Investing Activities	-153	-163	-111	-193	-140	-117	-376	-110	303	-176	-355
Purchase of Property, Plant & Equipment	-51	-41	-51	-60	-71	-64	-57	-74	-78	-115	-165
Acquisitions	-49	-76	-30	-15	-24	-33	-34	-31	-296	-18	-262
Purchase of Investments	-300	-350	-393	-538	-347	-224	-622	-420	-101	-114	-108
Sale and/or Maturity of Investments	246	335	363	384	301	203	338	415	778	71	179
Net Cash From Financing Activities	4.28	0.47	1.63	33	24	-39	54	-110	-232	-28	-679
Net Cash From Continuing Financing Activities	4.28	0.47	1.63	33	24	-39	54	-110	-232	-28	-679
Repayment of Debt	-	-	-	-	-	-	-	-	0.00	0.00	-450
Repurchase of Common Equity	-	-	-	0.00	0.00	-105	0.00	-144	-226	-86	-300
Other Financing Activities, net	4.28	0.47	1.63	33	24	66	54	35	-6.26	58	71
Cash Income Taxes Paid	57	50	59	31	34	25	45	78	101	159	99

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-27	188	-113	56	212	162	-323	-232	142	132	35
Net Cash From Operating Activities	50	105	52	54	204	210	177	78	250	249	202
Net Cash From Continuing Operating Activities	50	105	52	54	204	210	177	78	250	249	202
Net Income / (Loss) Continuing Operations	1.00	15	-7.12	32	52	27	75	203	119	141	124
Consolidated Net Income / (Loss)	1.00	15	-7.12	32	52	27	75	203	119	141	124
Depreciation Expense	37	71	55	64	67	68	66	71	71	69	70
Amortization Expense	19	61	60	60	67	53	6.71	5.97	6.91	6.96	0.00
Non-Cash Adjustments To Reconcile Net Income	28	1.84	32	23	14	50	19	-108	12	25	22
Changes in Operating Assets and Liabilities, net	-35	-44	-88	-124	3.28	12	10	-93	41	7.39	-14
Net Cash From Investing Activities	-81	321	-47	-10	-15	-104	131	-299	-76	-111	-183
Net Cash From Continuing Investing Activities	-81	321	-47	-10	-15	-104	131	-299	-76	-111	-183
Purchase of Property, Plant & Equipment	-22	-23	-29	-28	-42	-17	-36	-47	-36	-46	-40
Acquisitions	-293	-	-13	-4.89	-0.10	-	-5.00	-253	-4.67	-0.08	-4.91
Purchase of Investments	-19	-	-8.02	-4.16	-1.19	-100	-1.75	-	-35	-70	-146
Sale and/or Maturity of Investments	253	343	2.65	26	28	13	174	-	-	5.25	8.24
Net Cash From Financing Activities	1.43	-237	-116	8.71	20	60	-635	-25	-32	13	18
Net Cash From Continuing Financing Activities	1.43	-237	-116	8.71	20	60	-635	-25	-32	13	18
Repayment of Debt	-	-	0.00	-	-	-	-450	-20	20	-	0.00
Repurchase of Common Equity	-	-226	-83	-1.47	-	-1.00	-190	-25	-40	-45	0.00
Other Financing Activities, net	1.43	-12	-32	10	20	61	5.04	0.06	7.96	58	18
Effect of Exchange Rate Changes	2.12	-0.35	-3.31	3.77	4.07	-4.28	3.54	14	0.51	-	-3.09
Cash Income Taxes Paid	26	35	1.97	70	46	41	7.20	86	1.87	3.82	5.99

This table presents Globus Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	834	928	1,079	1,301	1,532	1,679	1,957	2,076	5,086	5,252	5,303
Total Current Assets	545	514	620	631	687	822	865	983	1,915	2,177	2,126
Cash & Equivalents	60	67	-	-	-	-	193	150	467	784	526
Short-Term Investments	221	223	255	200	116	187	250	296	50	106	31
Accounts Receivable	78	92	117	137	154	142	164	213	503	558	679
Inventories, net	105	113	108	131	196	229	237	299	848	659	759
Prepaid Expenses	7.35	15	11	15	17	18	18	21	45	50	65
Current Deferred & Refundable Income Taxes	47	3.80	8.72	7.29	8.10	6.42	1.22	4.06	1.64	21	65
Plant, Property, & Equipment, net	115	124	143	172	200	217	221	244	587	562	564
Total Noncurrent Assets	175	290	315	498	645	641	872	849	2,584	2,513	2,613
Long-Term Investments	49	60	56	263	410	359	562	496	75	66	72
Goodwill	92	106	124	124	129	157	180	197	1,435	1,432	1,435
Intangible Assets	33	62	79	87	79	87	69	64	925	795	745
Noncurrent Deferred & Refundable Income Taxes	0.00	31	20	14	5.93	6.62	24	49	11	94	218
Other Noncurrent Operating Assets	0.59	0.93	7.95	10	22	32	36	43	139	125	143
Total Liabilities & Shareholders' Equity	834	928	1,079	1,301	1,532	1,679	1,957	2,076	5,086	5,252	5,303
Total Liabilities	119	96	111	115	130	173	216	230	1,088	1,074	730
Total Current Liabilities	83	80	93	96	111	121	140	159	392	856	498
Accounts Payable	16	17	25	26	25	18	22	36	57	75	99
Accrued Expenses	54	46	53	60	63	78	91	92	240	261	334
Current Deferred Revenue	-	0.00	0.76	2.60	5.40	8.13	12	14	18	22	28
Current Deferred & Payable Income Tax Liabilities	0.76	1.91	3.27	0.92	1.06	1.10	1.05	0.99	3.85	11	4.16
Other Current Liabilities	12	14	11	6.83	17	15	14	16	73	44	34
Total Noncurrent Liabilities	36	16	18	19	18	52	76	71	696	219	231
Noncurrent Deferred & Payable Income Tax Liabilities	13	7.88	11	8.11	6.02	6.20	4.31	1.78	84	24	24
Other Noncurrent Operating Liabilities	23	7.79	6.98	11	12	46	71	69	194	195	207
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177	4,573
Total Preferred & Common Equity	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177	4,573
Total Common Equity	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177	4,573
Common Stock	193	212	238	300	357	457	554	631	2,871	3,031	3,170
Retained Earnings	525	629	736	893	1,048	1,045	1,194	1,240	1,137	1,153	1,388
Accumulated Other Comprehensive Income / (Loss)	-1.96	-8.64	-6.91	-7.17	-2.90	3.96	-6.77	-25	-10	-6.86	15

This table presents Globus Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,977	2,150	2,212	5,356	4,944	4,994	5,086	4,711	4,961	5,096	5,440
Total Current Assets	920	1,070	1,210	1,917	1,829	1,924	2,057	1,710	1,730	1,924	2,198
Cash & Equivalents	134	218	306	280	354	410	623	461	229	372	561
Short-Term Investments	271	287	306	189	80	83	72	0.00	0.00	19	69
Accounts Receivable	206	223	240	494	534	612	588	535	612	619	686
Inventories, net	282	321	336	905	816	770	718	664	772	772	773
Prepaid Expenses	24	19	20	48	43	46	51	47	68	74	60
Current Deferred & Refundable Income Taxes	2.20	3.04	1.76	1.74	0.37	2.50	5.15	3.02	49	69	49
Plant, Property, & Equipment, net	236	245	248	607	579	572	568	556	588	578	557
Total Noncurrent Assets	820	834	754	2,832	2,536	2,498	2,462	2,445	2,644	2,593	2,684
Long-Term Investments	504	480	392	276	51	28	12	0.00	0.00	17	169
Goodwill	182	199	199	1,122	1,451	1,454	1,432	1,433	1,435	1,434	1,439
Intangible Assets	54	59	55	1,262	888	867	843	772	796	774	721
Noncurrent Deferred & Refundable Income Taxes	45	51	62	7.32	11	18	45	117	276	232	215
Other Noncurrent Operating Assets	36	45	47	164	135	131	129	123	136	136	140
Total Liabilities & Shareholders' Equity	1,977	2,150	2,212	5,356	4,944	4,994	5,086	4,711	4,961	5,096	5,440
Total Liabilities	212	235	227	1,169	1,021	1,017	1,017	623	665	697	707
Total Current Liabilities	145	168	155	429	786	794	818	385	425	466	482
Accounts Payable	32	40	34	87	50	67	58	73	87	87	104
Accrued Expenses	88	84	90	222	210	216	255	238	282	326	313
Current Deferred Revenue	12	14	15	18	17	20	21	17	24	18	26
Current Deferred & Payable Income Tax Liabilities	1.31	16	1.76	34	43	11	4.17	13	0.00	1.29	3.03
Other Current Liabilities	11	14	15	68	42	49	43	44	32	33	36
Total Noncurrent Liabilities	67	67	72	740	235	223	199	238	241	231	225
Noncurrent Deferred & Payable Income Tax Liabilities	1.58	1.37	5.30	132	40	27	7.48	47	24	23	25
Other Noncurrent Operating Liabilities	66	66	67	198	195	196	191	192	216	208	200
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,764	1,915	1,985	4,187	3,922	3,976	4,069	4,088	4,296	4,399	4,732
Total Preferred & Common Equity	1,764	1,915	1,985	4,187	3,922	3,976	4,069	4,088	4,296	4,399	4,732
Total Common Equity	1,764	1,915	1,985	4,187	3,922	3,976	4,069	4,088	4,296	4,399	4,732
Common Stock	606	645	657	2,858	2,887	2,914	2,950	3,054	3,072	3,095	3,206
Retained Earnings	1,190	1,289	1,347	1,348	1,047	1,074	1,126	1,036	1,214	1,292	1,512
Accumulated Other Comprehensive Income / (Loss)	-32	-19	-19	-19	-11	-12	-6.96	-2.17	10	11	14

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.84%	3.53%	12.76%	12.11%	10.15%	0.47%	21.43%	6.76%	53.34%	60.62%	16.65%
EBITDA Growth	22.74%	-1.23%	5.58%	5.08%	2.54%	-21.76%	38.97%	24.07%	22.55%	67.38%	45.22%
EBIT Growth	24.59%	-10.38%	5.90%	7.35%	-1.59%	-35.12%	52.85%	33.71%	-36.51%	-14.01%	378.68%
NOPAT Growth	21.78%	-9.02%	-0.02%	37.40%	0.04%	-35.58%	57.07%	25.44%	-44.55%	43.16%	201.22%
Net Income Growth	21.95%	-7.49%	2.88%	45.76%	-0.81%	-34.10%	45.86%	27.47%	-35.39%	-16.19%	422.28%
EPS Growth	20.62%	-7.69%	1.85%	40.00%	-1.30%	-33.55%	42.57%	28.47%	-42.16%	-29.91%	422.67%
Operating Cash Flow Growth	56.63%	19.21%	7.60%	14.20%	-5.32%	15.59%	38.98%	-35.40%	36.44%	113.82%	44.72%
Free Cash Flow Firm Growth	-64.64%	-273.93%	335.48%	111.98%	-56.32%	21.89%	150.77%	-92.66%	-30,147.99%	110.62%	-50.93%
Invested Capital Growth	39.29%	33.79%	11.87%	8.32%	16.94%	5.81%	2.00%	22.98%	322.59%	-4.12%	7.63%
Revenue Q/Q Growth	2.60%	1.62%	4.00%	2.87%	2.04%	2.84%	1.76%	2.45%	27.89%	1.64%	6.11%
EBITDA Q/Q Growth	9.84%	-4.96%	1.91%	-0.99%	4.03%	7.86%	-14.40%	14.90%	29.58%	-2.21%	11.97%
EBIT Q/Q Growth	10.79%	-12.03%	8.96%	-2.92%	3.94%	9.24%	-19.55%	20.68%	-16.89%	-2.90%	31.17%
NOPAT Q/Q Growth	9.45%	-11.77%	-0.47%	7.07%	6.35%	9.64%	-20.23%	20.08%	-28.35%	61.69%	25.01%
Net Income Q/Q Growth	9.69%	-11.31%	0.07%	8.59%	6.00%	7.83%	-20.24%	22.52%	-22.18%	12.53%	26.92%
EPS Q/Q Growth	8.33%	-10.74%	0.00%	7.69%	4.83%	10.99%	-20.88%	21.71%	-30.52%	31.58%	26.45%
Operating Cash Flow Q/Q Growth	55.35%	-11.81%	13.16%	-0.30%	6.19%	14.96%	-1.40%	-6.44%	20.07%	25.46%	5.35%
Free Cash Flow Firm Q/Q Growth	129.26%	16.51%	-11.95%	35.90%	-16.74%	59.00%	-27.80%	-65.20%	1.41%	113.52%	-1.52%
Invested Capital Q/Q Growth	3.16%	-1.32%	-0.15%	-2.80%	0.00%	-1.50%	0.30%	5.80%	-0.78%	-3.55%	-1.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.71%	76.12%	76.34%	77.64%	77.08%	72.44%	75.03%	74.22%	65.05%	58.90%	67.41%
EBITDA Margin	36.63%	34.94%	32.71%	30.67%	28.55%	22.23%	25.44%	29.57%	23.63%	24.62%	30.65%
Operating Margin	31.61%	27.33%	25.45%	23.75%	21.90%	14.12%	17.95%	22.29%	8.49%	6.59%	16.33%
EBIT Margin	31.59%	27.34%	25.68%	24.59%	21.97%	14.19%	17.86%	22.37%	9.26%	4.96%	20.35%
Profit (Net Income) Margin	20.70%	18.50%	16.88%	21.95%	19.76%	12.96%	15.57%	18.59%	7.83%	4.09%	18.30%
Tax Burden Percent	65.27%	66.34%	63.17%	82.96%	81.71%	81.24%	82.70%	78.25%	74.29%	85.31%	88.89%
Interest Burden Percent	100.42%	101.98%	104.05%	107.57%	110.09%	112.46%	105.43%	106.22%	113.86%	96.65%	101.19%
Effective Tax Rate	34.73%	33.66%	36.83%	17.04%	18.29%	18.76%	17.30%	21.75%	25.71%	14.69%	11.11%
Return on Invested Capital (ROIC)	36.41%	24.34%	20.07%	25.07%	22.23%	12.91%	19.53%	21.75%	4.19%	3.78%	11.21%
ROIC Less NNEP Spread (ROIC-NNEP)	36.30%	23.75%	18.76%	21.97%	20.02%	11.35%	18.75%	20.54%	-0.10%	15.00%	-8.29%
Return on Net Nonoperating Assets (RNNOA)	-19.07%	-10.85%	-8.14%	-10.54%	-10.24%	-5.88%	-10.34%	-11.15%	0.02%	-1.26%	1.08%
Return on Equity (ROE)	17.34%	13.49%	11.93%	14.53%	11.99%	7.03%	9.19%	10.60%	4.20%	2.52%	12.29%
Cash Return on Invested Capital (CROIC)	3.57%	-4.56%	8.86%	17.08%	6.61%	7.27%	17.54%	1.14%	-119.27%	7.99%	3.86%
Operating Return on Assets (OROA)	22.38%	17.51%	16.28%	14.74%	12.18%	6.97%	9.41%	11.34%	4.06%	2.42%	11.33%
Return on Assets (ROA)	14.67%	11.85%	10.70%	13.15%	10.96%	6.37%	8.20%	9.43%	3.43%	1.99%	10.19%
Return on Common Equity (ROCE)	17.34%	13.48%	11.93%	14.53%	11.99%	7.03%	9.19%	10.60%	4.20%	2.52%	12.29%
Return on Equity Simple (ROE_SIMPLE)	15.77%	12.54%	11.09%	13.20%	11.07%	6.79%	8.57%	10.30%	3.07%	2.47%	0.00%
Net Operating Profit after Tax (NOPAT)	112	102	102	140	141	91	142	178	99	142	427
NOPAT Margin	20.63%	18.13%	16.08%	19.70%	17.89%	11.47%	14.84%	17.44%	6.31%	5.62%	14.51%
Net Nonoperating Expense Percent (NNEP)	0.11%	0.59%	1.31%	3.10%	2.22%	1.56%	0.78%	1.21%	4.29%	-11.22%	19.50%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.66%	2.24%	3.06%	9.33%
Cost of Revenue to Revenue	24.29%	23.88%	23.66%	22.36%	22.92%	27.56%	24.97%	25.78%	34.95%	41.10%	32.59%
SG&A Expenses to Revenue	38.59%	39.39%	42.11%	43.70%	45.17%	44.96%	42.60%	42.25%	41.02%	38.94%	40.10%
R&D to Revenue	6.67%	7.90%	6.87%	7.78%	7.65%	10.71%	10.16%	7.14%	7.91%	6.50%	5.01%
Operating Expenses to Revenue	44.09%	48.79%	50.90%	53.89%	55.18%	58.32%	57.08%	51.93%	56.56%	52.31%	51.08%
Earnings before Interest and Taxes (EBIT)	172	154	163	175	173	112	171	229	145	125	598
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	200	197	208	219	224	175	244	302	371	620	901
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.70	2.86	4.09	3.60	4.17	4.27	4.21	4.02	1.84	2.70	2.56
Price to Tangible Book Value (P/TBV)	4.49	3.58	5.18	4.37	4.90	5.10	4.91	4.68	4.48	5.78	4.88
Price to Revenue (P/Rev)	4.86	4.22	6.23	5.98	7.45	8.16	7.65	7.25	4.68	4.47	3.98
Price to Earnings (P/E)	23.49	22.79	36.90	27.24	37.71	62.92	49.11	38.99	59.76	109.36	21.73
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.26%	4.39%	2.71%	3.67%	2.65%	1.59%	2.04%	2.56%	1.67%	0.91%	4.60%
Enterprise Value to Invested Capital (EV/IC)	6.38	4.21	6.56	6.28	7.53	7.84	8.59	7.16	1.88	2.93	2.80
Enterprise Value to Revenue (EV/Rev)	4.21	3.59	5.55	5.13	6.53	7.16	6.60	6.33	4.57	4.27	3.76
Enterprise Value to EBITDA (EV/EBITDA)	11.50	10.28	16.97	16.74	22.89	32.21	25.93	21.40	19.34	17.33	12.27
Enterprise Value to EBIT (EV/EBIT)	13.33	13.14	21.62	20.87	29.75	50.47	36.94	28.29	49.34	86.06	18.49
Enterprise Value to NOPAT (EV/NOPAT)	20.40	19.81	34.54	26.05	36.52	62.41	44.45	36.29	72.46	75.91	25.92
Enterprise Value to Operating Cash Flow (EV/OCF)	18.50	13.71	22.20	20.15	29.84	28.42	22.88	36.27	29.43	20.65	14.67
Enterprise Value to Free Cash Flow (EV/FCFF)	208.08	0.00	78.22	38.24	122.78	110.90	49.47	690.06	0.00	35.92	75.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.11	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00
Financial Leverage	-0.53	-0.46	-0.43	-0.48	-0.51	-0.52	-0.55	-0.54	-0.19	-0.08	-0.13
Leverage Ratio	1.18	1.14	1.11	1.10	1.09	1.10	1.12	1.12	1.23	1.26	1.21
Compound Leverage Factor	1.19	1.16	1.16	1.19	1.21	1.24	1.18	1.19	1.40	1.22	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.45%	9.59%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.59%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.45%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.99%	99.99%	99.99%	100.00%	100.00%	99.99%	100.00%	100.00%	90.55%	90.41%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.71	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.47	-0.83	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	3.13	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.78	-3.62	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	0.00	0.00
Altman Z-Score	16.26	17.59	24.10	24.66	29.39	24.36	22.44	21.53	5.12	7.46	11.27
Noncontrolling Interest Sharing Ratio	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.59	6.43	6.67	6.56	6.17	6.80	6.17	6.18	4.88	2.54	4.26
Quick Ratio	4.34	4.79	4.01	3.51	2.42	2.72	4.34	4.14	2.60	1.69	2.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	-19	45	96	42	51	128	9.38	-2,819	299	147
Operating Cash Flow to CapEx	244.30%	361.35%	310.04%	332.09%	243.07%	312.28%	485.56%	241.02%	311.09%	451.05%	457.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	71.44	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	124.29	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	96.73	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.71	0.64	0.63	0.60	0.55	0.49	0.53	0.51	0.44	0.49	0.56
Accounts Receivable Turnover	7.12	6.65	6.10	5.62	5.39	5.33	6.26	5.42	4.38	4.75	4.75
Inventory Turnover	1.35	1.24	1.36	1.33	1.10	1.02	1.03	0.98	0.96	1.37	1.35
Fixed Asset Turnover	5.91	4.72	4.76	4.53	4.23	3.79	4.38	4.40	3.78	4.39	5.22
Accounts Payable Turnover	7.11	8.06	7.08	6.26	7.13	10.16	11.91	9.09	11.82	15.71	11.01
Days Sales Outstanding (DSO)	51.29	54.90	59.88	64.95	67.71	68.46	58.31	67.39	83.37	76.85	76.79
Days Inventory Outstanding (DIO)	270.59	295.28	268.20	274.38	332.16	357.06	355.62	370.90	381.90	265.67	270.28
Days Payable Outstanding (DPO)	51.35	45.31	51.57	58.31	51.22	35.93	30.64	40.18	30.89	23.23	33.15
Cash Conversion Cycle (CCC)	270.53	304.88	276.51	281.02	348.66	389.59	383.29	398.12	434.38	319.29	313.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	359	481	538	583	681	721	735	904	3,822	3,664	3,944
Invested Capital Turnover	1.76	1.34	1.25	1.27	1.24	1.13	1.32	1.25	0.66	0.67	0.77
Increase / (Decrease) in Invested Capital	101	121	57	45	99	40	14	169	2,918	-158	280
Enterprise Value (EV)	2,294	2,026	3,531	3,659	5,132	5,650	6,320	6,473	7,167	10,750	11,056
Market Capitalization	2,649	2,377	3,961	4,262	5,853	6,436	7,326	7,415	7,343	11,262	11,685
Book Value per Share	$7.51	$8.68	$10.04	$12.04	$14.11	$15.26	$17.16	$18.49	$29.01	$30.68	$34.17
Tangible Book Value per Share	$6.20	$6.93	$7.94	$9.89	$12.02	$12.79	$14.71	$15.88	$11.89	$14.32	$17.88
Total Capital	715	832	968	1,186	1,402	1,506	1,741	1,846	4,415	4,621	4,573
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	417	443	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	417	0.00	0.00
Net Debt	-356	-351	-430	-603	-721	-785	-1,006	-942	-176	-513	-629
Capital Expenditures (CapEx)	51	41	51	55	71	64	57	74	78	115	165
Debt-free, Cash-free Net Working Capital (DFCFNWC)	155	143	154	195	265	274	281	378	1,005	875	1,070
Debt-free Net Working Capital (DFNWC)	462	434	527	535	576	701	724	824	1,523	1,765	1,627
Net Working Capital (NWC)	462	434	527	535	576	701	724	824	1,523	1,321	1,627
Net Nonoperating Expense (NNE)	-0.38	-2.08	-5.11	-16	-15	-12	-6.99	-12	-24	39	-111
Net Nonoperating Obligations (NNO)	-356	-351	-430	-603	-721	-785	-1,006	-942	-176	-513	-629
Total Depreciation and Amortization (D&A)	27	43	45	43	52	63	73	74	225	495	303
Debt-free, Cash-free Net Working Capital to Revenue	28.45%	25.37%	24.15%	27.33%	33.69%	34.76%	29.32%	36.96%	64.09%	34.72%	36.40%
Debt-free Net Working Capital to Revenue	84.83%	76.93%	82.91%	74.98%	73.35%	88.84%	75.60%	80.57%	97.10%	70.05%	55.36%
Net Working Capital to Revenue	84.83%	76.93%	82.91%	74.98%	73.35%	88.84%	75.60%	80.57%	97.10%	52.45%	55.36%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.19	$1.09	$1.12	$1.60	$1.57	$1.04	$1.48	$1.89	$1.09	$0.76	$3.98
Adjusted Weighted Average Basic Shares Outstanding	95.05M	95.65M	96.24M	97.88M	99.15M	98.58M	100.73M	100.47M	113.09M	135.73M	135.22M
Adjusted Diluted Earnings per Share	$1.17	$1.08	$1.10	$1.54	$1.52	$1.01	$1.44	$1.85	$1.07	$0.75	$3.92
Adjusted Weighted Average Diluted Shares Outstanding	96.07M	96.43M	97.89M	101.32M	102.00M	100.97M	103.62M	102.64M	114.63M	137.86M	137.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	95.37M	95.97M	96.73M	98.65M	99.84M	99.80M	101.56M	100.30M	135.37M	137.54M	135.25M
Normalized Net Operating Profit after Tax (NOPAT)	107	106	105	147	144	94	161	185	150	187	478
Normalized NOPAT Margin	19.69%	18.72%	16.50%	20.58%	18.39%	11.89%	16.82%	18.07%	9.56%	7.44%	16.25%
Pre Tax Income Margin	31.72%	27.89%	26.72%	26.45%	24.19%	15.96%	18.83%	23.76%	10.54%	4.79%	20.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.82	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.80	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.26	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.25	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	102.33%	0.00%	75.98%	183.57%	83.30%	55.86%

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	135,253,051.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	135,253,051.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.92
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	50.95%	124.60%	119.26%	115.93%	63.10%	6.61%	-1.41%	18.37%	22.91%	25.73%	27.04%
EBITDA Growth	-33.21%	112.89%	44.72%	105.04%	276.51%	-8.79%	60.03%	51.95%	14.84%	66.20%	27.04%
EBIT Growth	-109.35%	-51.71%	-111.75%	-24.80%	1,173.48%	-13.50%	1,630.42%	275.59%	146.58%	595.63%	48.69%
NOPAT Growth	-99.65%	-86.02%	-87.23%	-35.27%	27,385.65%	963.68%	1,161.39%	147.70%	159.60%	117.22%	68.54%
Net Income Growth	-97.90%	-69.97%	-114.49%	-44.97%	5,093.99%	76.30%	1,160.31%	538.68%	129.50%	430.44%	64.72%
EPS Growth	-97.87%	-97.92%	-110.42%	-59.65%	3,700.00%	1,800.00%	1,180.00%	547.83%	131.58%	431.58%	66.67%
Operating Cash Flow Growth	53.35%	63.62%	-1.74%	54.90%	303.40%	100.95%	238.44%	43.51%	22.61%	18.18%	14.14%
Free Cash Flow Firm Growth	-3,868.12%	-2,220.88%	-2,309.60%	-2,461.71%	103.21%	107.64%	110.41%	96.59%	-181.62%	-162.50%	-161.48%
Invested Capital Growth	350.61%	322.59%	314.94%	296.25%	-1.37%	-4.12%	-6.06%	4.63%	5.06%	7.63%	8.44%
Revenue Q/Q Growth	31.56%	60.71%	-1.60%	3.80%	-0.63%	5.05%	-9.00%	24.61%	3.18%	7.46%	-8.05%
EBITDA Q/Q Growth	-39.82%	212.80%	-31.72%	59.52%	10.51%	-24.22%	19.79%	51.47%	-16.48%	9.66%	-8.43%
EBIT Q/Q Growth	-108.11%	612.09%	-124.17%	849.04%	15.81%	-58.74%	327.58%	83.83%	-23.97%	16.40%	-8.61%
NOPAT Q/Q Growth	-99.69%	3,728.22%	-8.06%	491.69%	31.98%	48.15%	9.03%	16.19%	38.33%	23.96%	-15.40%
Net Income Q/Q Growth	-98.27%	1,406.41%	-147.34%	546.26%	63.21%	-48.87%	184.71%	168.81%	-41.35%	18.18%	-11.59%
EPS Q/Q Growth	-98.25%	0.00%	-600.00%	560.00%	65.22%	-50.00%	184.21%	175.93%	-40.94%	14.77%	-10.89%
Operating Cash Flow Q/Q Growth	44.12%	107.34%	-49.95%	3.57%	275.34%	3.28%	-15.71%	-56.08%	220.68%	-0.44%	-18.59%
Free Cash Flow Firm Q/Q Growth	-2,573.02%	2.85%	-0.45%	1.79%	103.35%	130.97%	36.90%	-132.21%	19.86%	-76.87%	-34.67%
Invested Capital Q/Q Growth	292.79%	-0.78%	1.01%	0.66%	-2.23%	-3.55%	-1.03%	12.12%	-1.84%	-1.19%	-0.28%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	64.71%	56.94%	60.19%	58.70%	56.77%	59.92%	67.33%	66.62%	67.16%	68.41%	69.20%
EBITDA Margin	13.30%	25.88%	17.96%	27.60%	30.70%	22.14%	29.15%	35.43%	28.68%	29.27%	29.15%
Operating Margin	0.11%	1.64%	1.32%	7.88%	7.69%	9.17%	16.22%	10.21%	17.86%	20.49%	19.79%
EBIT Margin	-1.40%	4.47%	-1.10%	7.93%	9.24%	3.63%	17.05%	25.15%	18.53%	20.08%	19.96%
Profit (Net Income) Margin	0.26%	2.44%	-1.17%	5.04%	8.28%	4.03%	12.62%	27.22%	15.47%	17.01%	16.36%
Tax Burden Percent	39.37%	60.15%	83.16%	66.75%	90.89%	107.45%	72.79%	107.80%	82.62%	83.08%	79.14%
Interest Burden Percent	-47.08%	90.64%	128.42%	95.32%	98.66%	103.42%	101.65%	100.37%	101.02%	102.00%	103.58%
Effective Tax Rate	60.63%	39.85%	0.00%	33.25%	9.11%	-7.45%	27.21%	-7.80%	17.38%	16.92%	20.86%
Return on Invested Capital (ROIC)	0.02%	0.66%	0.73%	4.83%	4.53%	6.63%	7.92%	7.27%	10.49%	13.15%	12.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.11%	-0.95%	3.16%	5.08%	1.84%	17.74%	6.06%	-68.30%	8.87%	13.17%	12.01%
Return on Net Nonoperating Assets (RNNOA)	0.02%	0.18%	-0.57%	-0.93%	-0.14%	-1.49%	-0.40%	2.64%	-0.71%	-1.72%	-1.72%
Return on Equity (ROE)	0.05%	0.84%	0.16%	3.90%	4.39%	5.14%	7.52%	9.91%	9.78%	11.43%	11.13%
Cash Return on Invested Capital (CROIC)	-121.49%	-119.27%	-119.80%	-117.68%	3.66%	7.99%	11.67%	2.23%	3.83%	3.86%	4.47%
Operating Return on Assets (OROA)	-0.47%	1.96%	-0.59%	4.92%	4.39%	1.77%	8.87%	13.27%	10.08%	11.18%	12.19%
Return on Assets (ROA)	0.09%	1.07%	-0.63%	3.13%	3.93%	1.97%	6.56%	14.36%	8.42%	9.47%	9.99%
Return on Common Equity (ROCE)	0.05%	0.84%	0.16%	3.90%	4.39%	5.14%	7.52%	9.91%	9.78%	11.43%	11.13%
Return on Equity Simple (ROE_SIMPLE)	3.77%	0.00%	1.70%	1.02%	2.25%	0.00%	4.54%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	0.16	6.09	5.60	33	44	65	71	82	113	141	119
NOPAT Margin	0.04%	0.99%	0.92%	5.26%	6.99%	9.85%	11.81%	11.01%	14.76%	17.02%	15.66%
Net Nonoperating Expense Percent (NNEP)	0.13%	1.60%	-2.43%	-0.25%	2.68%	-11.11%	1.86%	75.57%	1.62%	-0.02%	0.84%
Return On Investment Capital (ROIC_SIMPLE)	-	0.14%	-	-	-	1.40%	1.73%	1.91%	2.58%	3.08%	2.51%
Cost of Revenue to Revenue	35.29%	43.06%	39.81%	41.30%	43.23%	40.08%	32.67%	33.38%	32.84%	31.60%	30.80%
SG&A Expenses to Revenue	40.72%	39.69%	41.00%	37.82%	38.47%	38.56%	40.59%	40.74%	40.78%	38.54%	39.19%
R&D to Revenue	7.64%	8.48%	9.44%	5.99%	5.65%	5.08%	5.53%	5.36%	4.95%	4.38%	4.80%
Operating Expenses to Revenue	64.60%	55.30%	58.88%	50.82%	49.08%	50.75%	51.11%	56.41%	49.30%	47.91%	49.40%
Earnings before Interest and Taxes (EBIT)	-5.39	28	-6.66	50	58	24	102	187	143	166	152
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	51	160	109	174	192	146	174	264	221	242	221
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.19	1.84	1.88	2.33	2.38	2.70	2.46	1.86	1.76	2.56	2.46
Price to Tangible Book Value (P/TBV)	2.77	4.48	4.67	5.59	5.40	5.78	5.35	3.87	3.53	4.88	4.53
Price to Revenue (P/Rev)	4.07	4.68	3.89	4.14	3.91	4.47	4.01	3.04	2.79	3.98	3.76
Price to Earnings (P/E)	31.59	59.76	110.93	227.41	105.85	109.36	54.26	22.40	18.25	21.73	19.86
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.17%	1.67%	0.90%	0.44%	0.94%	0.91%	1.84%	4.46%	5.48%	4.60%	5.03%
Enterprise Value to Invested Capital (EV/IC)	1.21	1.88	1.90	2.36	2.48	2.93	2.65	1.91	1.84	2.80	2.76
Enterprise Value to Revenue (EV/Rev)	3.79	4.57	3.86	4.10	3.80	4.27	3.83	2.95	2.65	3.76	3.50
Enterprise Value to EBITDA (EV/EBITDA)	16.27	19.34	18.13	18.57	14.84	17.33	14.01	10.00	9.11	12.27	11.45
Enterprise Value to EBIT (EV/EBIT)	26.62	49.34	89.49	139.97	73.21	86.06	41.13	20.91	16.07	18.49	16.76
Enterprise Value to NOPAT (EV/NOPAT)	33.70	72.46	121.58	219.93	107.53	75.91	47.29	28.88	21.48	25.92	22.85
Enterprise Value to Operating Cash Flow (EV/OCF)	22.94	29.43	30.22	34.99	22.69	20.65	14.88	11.60	10.25	14.67	13.94
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	67.19	35.92	21.98	87.55	49.14	75.30	64.28
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.10	0.11	0.11	0.11	0.11	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.10	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.21	-0.19	-0.18	-0.18	-0.07	-0.08	-0.07	-0.04	-0.08	-0.13	-0.14
Leverage Ratio	1.23	1.23	1.22	1.21	1.26	1.26	1.21	1.20	1.20	1.21	1.15
Compound Leverage Factor	-0.58	1.11	1.56	1.15	1.25	1.31	1.23	1.21	1.21	1.23	1.19
Debt to Total Capital	8.91%	9.45%	9.76%	9.77%	9.70%	9.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	9.76%	9.77%	9.70%	9.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.91%	9.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.09%	90.55%	90.24%	90.23%	90.30%	90.41%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	1.43	1.13	1.05	0.87	0.69	0.71	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-1.17	-0.47	-0.15	-0.18	-0.43	-0.83	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	1.43	1.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	2.97	4.22	7.03	10.34	4.99	3.13	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-2.43	-1.78	-1.02	-2.17	-3.08	-3.62	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	2.97	4.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.47	5.05	5.27	6.51	6.84	7.39	10.95	8.52	7.99	11.00	11.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.47	4.88	2.33	2.42	2.51	2.54	4.45	4.07	4.13	4.26	4.56
Quick Ratio	2.25	2.60	1.23	1.39	1.57	1.69	2.59	1.98	2.17	2.48	2.73
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,997	-2,912	-2,925	-2,872	96	222	304	-98	-79	-139	-187
Operating Cash Flow to CapEx	234.44%	457.47%	183.38%	195.19%	485.45%	1,229.26%	491.09%	167.23%	697.14%	538.10%	510.83%
Free Cash Flow to Firm to Interest Expense	0.00	-1,128.09	-1,544.17	-1,230.10	124.25	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	40.56	27.66	23.24	262.78	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	31.69	12.58	11.33	208.65	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.44	0.54	0.62	0.47	0.49	0.52	0.53	0.54	0.56	0.61
Accounts Receivable Turnover	3.50	4.38	5.02	5.25	4.58	4.75	4.70	4.29	4.59	4.75	5.08
Inventory Turnover	0.60	0.96	1.26	1.63	1.28	1.37	1.34	1.27	1.29	1.35	1.39
Fixed Asset Turnover	2.91	3.78	4.61	5.46	4.22	4.39	4.42	4.53	4.84	5.22	5.57
Accounts Payable Turnover	5.94	11.82	15.92	17.87	14.36	15.71	16.01	12.68	13.26	11.01	11.27
Days Sales Outstanding (DSO)	104.23	83.37	72.78	69.52	79.68	76.85	77.73	85.00	79.54	76.79	71.90
Days Inventory Outstanding (DIO)	613.39	381.90	288.72	223.68	285.43	265.67	272.96	287.82	283.07	270.28	263.04
Days Payable Outstanding (DPO)	61.43	30.89	22.93	20.42	25.41	23.23	22.80	28.78	27.52	33.15	32.38
Cash Conversion Cycle (CCC)	656.19	434.38	338.57	272.78	339.70	319.29	327.89	344.04	335.09	313.93	302.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,852	3,822	3,861	3,886	3,800	3,664	3,627	4,066	3,992	3,944	3,933
Invested Capital Turnover	0.52	0.66	0.79	0.92	0.65	0.67	0.67	0.66	0.71	0.77	0.82
Increase / (Decrease) in Invested Capital	2,997	2,918	2,930	2,905	-53	-158	-234	180	192	280	306
Enterprise Value (EV)	4,653	7,167	7,330	9,160	9,417	10,750	9,607	7,761	7,328	11,056	10,854
Market Capitalization	4,988	7,343	7,391	9,250	9,687	11,262	10,068	7,990	7,735	11,685	11,653
Book Value per Share	$41.68	$29.01	$28.98	$29.44	$30.05	$30.68	$29.72	$31.73	$32.57	$34.17	$34.99
Tangible Book Value per Share	$17.95	$11.89	$11.70	$12.26	$13.26	$14.32	$13.69	$15.25	$16.22	$17.88	$19.02
Total Capital	4,597	4,415	4,346	4,407	4,507	4,621	4,088	4,296	4,399	4,573	4,732
Total Debt	410	417	424	430	437	443	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	410	417	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-335	-176	-62	-90	-270	-513	-461	-229	-407	-629	-799
Capital Expenditures (CapEx)	22	23	29	28	42	17	36	47	36	46	40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,020	1,005	1,032	1,067	981	875	864	1,076	1,068	1,070	1,086
Debt-free Net Working Capital (DFNWC)	1,489	1,523	1,466	1,560	1,676	1,765	1,325	1,305	1,458	1,627	1,716
Net Working Capital (NWC)	1,489	1,523	1,042	1,130	1,238	1,321	1,325	1,305	1,458	1,627	1,716
Net Nonoperating Expense (NNE)	-0.84	-8.95	13	1.36	-8.12	38	-4.85	-121	-5.48	0.09	-5.29
Net Nonoperating Obligations (NNO)	-335	-176	-62	-90	-270	-513	-461	-229	-407	-629	-799
Total Depreciation and Amortization (D&A)	56	132	116	124	134	122	72	77	78	76	70
Debt-free, Cash-free Net Working Capital to Revenue	83.14%	64.09%	54.35%	47.72%	39.57%	34.72%	34.42%	40.96%	38.55%	36.40%	35.02%
Debt-free Net Working Capital to Revenue	121.38%	97.10%	77.24%	69.76%	67.60%	70.05%	52.79%	49.70%	52.65%	55.36%	55.33%
Net Working Capital to Revenue	121.38%	97.10%	54.90%	50.51%	49.97%	52.45%	52.79%	49.70%	52.65%	55.36%	55.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.01	$0.02	($0.05)	$0.23	$0.38	$0.20	$0.55	$1.50	$0.88	$1.05	$0.92
Adjusted Weighted Average Basic Shares Outstanding	113.54M	113.09M	135.36M	135.20M	135.62M	135.73M	136.76M	135.21M	134.50M	135.22M	135.36M
Adjusted Diluted Earnings per Share	$0.01	$0.01	($0.05)	$0.23	$0.38	$0.19	$0.54	$1.49	$0.88	$1.01	$0.90
Adjusted Weighted Average Diluted Shares Outstanding	115.25M	114.63M	135.36M	136.98M	138.06M	137.86M	139.77M	136.50M	135.39M	137.06M	138.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.79M	135.37M	135.06M	135.41M	136.17M	137.54M	135.38M	135.06M	133.84M	135.25M	135.74M
Normalized Net Operating Profit after Tax (NOPAT)	34	16	21	43	45	54	71	86	112	151	128
Normalized NOPAT Margin	8.93%	2.53%	3.41%	6.80%	7.12%	8.21%	11.93%	11.53%	14.50%	18.23%	16.87%
Pre Tax Income Margin	0.66%	4.05%	-1.41%	7.56%	9.11%	3.75%	17.33%	25.25%	18.72%	20.48%	20.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	10.68	-3.52	21.38	74.59	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	2.36	2.96	14.19	56.41	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	1.82	-18.60	9.47	20.46	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-6.51	-12.13	2.28	2.28	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	183.57%	463.59%	763.00%	339.13%	83.30%	103.97%	60.69%	60.52%	55.86%	18.75%

Financials Breakdown Chart

Key Financial Trends

Globus Medical (NYSE: GMED) delivered a solid start to 2026, with revenue growth, strong profitability, and robust cash generation. Over the past four years, the company has shown meaningful top-line expansion, but results also reflect the impact of acquisitions, restructuring charges, and some volatility in working capital and debt.

What stands out most: GMED has grown from a company generating roughly $277 million in quarterly revenue in Q1 2023 to about $760 million in Q1 2026. At the same time, it has remained profitable and produced strong operating cash flow, which is a good sign for investors looking at long-term execution.

Revenue continues to scale: Q1 2026 revenue was $759.9 million, up from $598.1 million in Q1 2025 and well above $276.7 million in Q1 2023, showing strong multi-year growth.
Gross profit remains healthy: Q1 2026 gross profit of $525.8 million implies a strong gross margin profile, even with a sizable cost base.
Operating cash flow is strong: Q1 2026 operating cash flow reached $202.4 million, supporting the company’s ability to fund growth internally.
Balance sheet has strengthened versus early 2024: Total equity rose to $4.73 billion in Q1 2026 from $3.92 billion in Q1 2024, reflecting continued earnings retention and capital growth.
Liquidity is ample: The company ended Q1 2026 with $560.9 million in cash and equivalents plus $68.9 million in short-term investments.
Profitability improved sharply over the last two years: GMED went from a Q1 2024 loss of $7.1 million to Q1 2026 net income of $124.3 million.
EPS remains constructive: Q1 2026 diluted EPS was $0.90, versus $0.54 in Q1 2025 and a loss in Q1 2024.
Acquisitions remain part of the story: GMED spent $4.9 million on acquisitions in Q1 2026, following much larger acquisition activity in prior periods, suggesting ongoing portfolio expansion.
Investment activity is significant: The company purchased $146.4 million of investments in Q1 2026, which may help manage liquidity but also reduces cash temporarily.
Working capital remains a big investment: Inventories were $772.6 million and receivables were $686.4 million in Q1 2026, so a large amount of capital is tied up in operations.
Operating expenses remain heavy: Q1 2026 SG&A was $297.8 million, and total operating expenses were $375.4 million, which keeps pressure on margins despite strong revenue growth.
Restructuring charges have been recurring: GMED has reported restructuring charges in multiple periods, including $11.6 million in Q1 2026 and $11.9 million in Q4 2025, indicating ongoing integration or cost-reduction efforts.
Debt history was volatile: The company had meaningful short-term debt in 2024, including $437.1 million in Q3 2024, though debt appears to have been reduced or eliminated by 2025-2026.

Longer-term trend: GMED’s revenue growth has been impressive, especially after the 2024-2025 period when the company appears to have absorbed acquisitions and restructured operations. Revenue roughly doubled from early 2023 to early 2026, while net income also moved from volatile and sometimes negative results to consistently strong profitability.

Cash flow quality is a key strength. GMED has repeatedly generated positive operating cash flow, including $177.3 million in Q1 2025, $248.6 million in Q4 2025, and $202.4 million in Q1 2026. That gives the company flexibility to invest in CapEx, acquisitions, and share-related activity while maintaining a healthy cash position.

Investor takeaway: GMED looks like a company with strong growth momentum, good liquidity, and improving earnings power. The main things to watch are operating expense discipline, the pace of acquisition-driven growth, and whether restructuring charges eventually fade. If margins stay strong as revenue grows, the stock’s fundamental picture could remain attractive.

06/08/26 09:04 PM ETAI Generated. May Contain Errors.

Globus Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Globus Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Globus Medical's net income appears to be on an upward trend, with a most recent value of $537.87 million in 2025, rising from $112.78 million in 2015. The previous period was $102.98 million in 2024. Check out Globus Medical's forecast to explore projected trends and price targets.

Globus Medical's total operating income in 2025 was $479.82 million, based on the following breakdown:

Total Gross Profit: $1.98 billion
Total Operating Expenses: $1.50 billion

Over the last 10 years, Globus Medical's total revenue changed from $544.75 million in 2015 to $2.94 billion in 2025, a change of 439.5%.

Globus Medical's total liabilities were at $729.51 million at the end of 2025, a 32.1% decrease from 2024, and a 514.2% increase since 2015.

In the past 10 years, Globus Medical's cash and equivalents has ranged from $0.00 in 2017 to $784.44 million in 2024, and is currently $526.16 million as of their latest financial filing in 2025.

Over the last 10 years, Globus Medical's book value per share changed from 7.51 in 2015 to 34.17 in 2025, a change of 355.0%.

Related Companies

Financial statements for NYSE:GMED last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Financials

Financials Breakdown Chart

Key Financial Trends

Globus Medical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Financials

Annual Income Statements for Globus Medical

Quarterly Income Statements for Globus Medical

Annual Cash Flow Statements for Globus Medical

Quarterly Cash Flow Statements for Globus Medical

Annual Balance Sheets for Globus Medical

Quarterly Balance Sheets for Globus Medical

Annual Metrics And Ratios for Globus Medical

Quarterly Metrics And Ratios for Globus Medical

Financials Breakdown Chart

Key Financial Trends

Globus Medical Financials - Frequently Asked Questions

When does Globus Medical's financial year end?

How has Globus Medical's net income changed over the last 10 years?

What is Globus Medical's operating income?

How has Globus Medical's revenue changed over the last 10 years?

How much debt does Globus Medical have?

How much cash does Globus Medical have?

How has Globus Medical's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools